1. Home
  2. SILO vs SNGX Comparison

SILO vs SNGX Comparison

Compare SILO & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SILO
  • SNGX
  • Stock Information
  • Founded
  • SILO 2010
  • SNGX 1987
  • Country
  • SILO United States
  • SNGX United States
  • Employees
  • SILO N/A
  • SNGX N/A
  • Industry
  • SILO Apparel
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SILO Consumer Discretionary
  • SNGX Health Care
  • Exchange
  • SILO Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • SILO 8.8M
  • SNGX 7.4M
  • IPO Year
  • SILO N/A
  • SNGX 1987
  • Fundamental
  • Price
  • SILO $1.65
  • SNGX $2.32
  • Analyst Decision
  • SILO
  • SNGX
  • Analyst Count
  • SILO 0
  • SNGX 0
  • Target Price
  • SILO N/A
  • SNGX N/A
  • AVG Volume (30 Days)
  • SILO 805.4K
  • SNGX 620.7K
  • Earning Date
  • SILO 02-18-2025
  • SNGX 03-14-2025
  • Dividend Yield
  • SILO N/A
  • SNGX N/A
  • EPS Growth
  • SILO N/A
  • SNGX N/A
  • EPS
  • SILO N/A
  • SNGX N/A
  • Revenue
  • SILO $72,102.00
  • SNGX $364,183.00
  • Revenue This Year
  • SILO $1.86
  • SNGX N/A
  • Revenue Next Year
  • SILO N/A
  • SNGX $76.64
  • P/E Ratio
  • SILO N/A
  • SNGX N/A
  • Revenue Growth
  • SILO N/A
  • SNGX N/A
  • 52 Week Low
  • SILO $0.77
  • SNGX $0.32
  • 52 Week High
  • SILO $4.50
  • SNGX $14.83
  • Technical
  • Relative Strength Index (RSI)
  • SILO 52.57
  • SNGX 36.12
  • Support Level
  • SILO $1.56
  • SNGX $2.23
  • Resistance Level
  • SILO $1.89
  • SNGX $2.39
  • Average True Range (ATR)
  • SILO 0.19
  • SNGX 0.17
  • MACD
  • SILO -0.05
  • SNGX 0.01
  • Stochastic Oscillator
  • SILO 27.12
  • SNGX 22.12

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: